Abstract：
UNASSIGNED: In patients with atrial fibrillation (AF), direct oral anticoagulants (DOACs) have been utilized as an alternative to warfarin, which is known to have several limitations. This study aimed to clarify the selection criteria for anticoagulants, considering both individual patient factors and the differences between various drugs.
UNASSIGNED: This study conducted a web-based questionnaire from September 20, 2023 to October 3, 2023, among physicians who were members of a cardiology-specific website.
UNASSIGNED: In total, 172 respondents were enrolled in this study. Edoxaban was the most frequently selected anticoagulant (39.1%), followed by apixaban (32.7%) and rivaroxaban (16.8%). Logistic regression analysis revealed that increased concern for adherence enhanced the frequency of selecting edoxaban (odds ratio [OR] = 2.42; p = 0.047), with the opposite trend observed for dabigatran (OR = 0.404; p = 0.029). The selection of apixaban is related to whether the patient is able to maintain a regular lifestyle, including adherence to medication schedules (OR = 1.874; p = 0.031). Furthermore, detailing activities from a medical representative, especially regarding a new indication, were found to influence drug selection for rivaroxaban (OR = 2.422; p = 0.047).
UNASSIGNED: This study revealed that edoxaban is the most frequently selected anticoagulant. Although prescribing cardiologists select drugs based on background factors, adherence to medication and information from medical representatives were also crucial factors in the selection process.
UNASSIGNED: This study conducted a web-based questionnaire from September 20, 2023 to October 3, 2023, among physicians who were members of a cardiology-specific website.
UNASSIGNED: In total, 172 respondents were enrolled in this study. Edoxaban was the most frequently selected anticoagulant (39.1%), followed by apixaban (32.7%) and rivaroxaban (16.8%). Logistic regression analysis revealed that increased concern for adherence enhanced the frequency of selecting edoxaban (odds ratio [OR] = 2.42; p = 0.047), with the opposite trend observed for dabigatran (OR = 0.404; p = 0.029). The selection of apixaban is related to whether the patient is able to maintain a regular lifestyle, including adherence to medication schedules (OR = 1.874; p = 0.031). Furthermore, detailing activities from a medical representative, especially regarding a new indication, were found to influence drug selection for rivaroxaban (OR = 2.422; p = 0.047).
UNASSIGNED: This study revealed that edoxaban is the most frequently selected anticoagulant. Although prescribing cardiologists select drugs based on background factors, adherence to medication and information from medical representatives were also crucial factors in the selection process.
摘要：
■在房颤（AF）患者中，直接口服抗凝剂（DOAC）已被用作华法林的替代品，这是已知的有几个限制。本研究旨在阐明抗凝剂的选择标准，考虑到患者的个体因素和各种药物之间的差异。
■这项研究于2023年9月20日至2023年10月3日进行了一项基于网络的问卷调查，其中包括作为心脏病学特定网站成员的医生。
■总共，172名受访者参加了这项研究。依多沙班是最常用的抗凝剂（39.1%），其次是阿哌沙班(32.7%)和利伐沙班(16.8%)。Logistic回归分析显示，对依从性的关注增加了选择依多沙班的频率（比值比[OR]=2.42；p=0.047），达比加群的趋势相反(OR=0.404；p=0.029)。阿哌沙班的选择与患者是否能够保持规律的生活方式有关，包括对用药计划的依从性（OR=1.874；p=0.031）。此外，详细说明医疗代表的活动，特别是关于一个新的适应症，发现影响利伐沙班的药物选择（OR=2.422；p=0.047）。
■这项研究表明，依度沙班是最常用的抗凝剂。虽然处方心脏病专家根据背景因素选择药物，对药物治疗的依从性和来自医学代表的信息也是选择过程中的关键因素.
■这项研究于2023年9月20日至2023年10月3日进行了一项基于网络的问卷调查，其中包括作为心脏病学特定网站成员的医生。
■总共，172名受访者参加了这项研究。依多沙班是最常用的抗凝剂（39.1%），其次是阿哌沙班(32.7%)和利伐沙班(16.8%)。Logistic回归分析显示，对依从性的关注增加了选择依多沙班的频率（比值比[OR]=2.42；p=0.047），达比加群的趋势相反(OR=0.404；p=0.029)。阿哌沙班的选择与患者是否能够保持规律的生活方式有关，包括对用药计划的依从性（OR=1.874；p=0.031）。此外，详细说明医疗代表的活动，特别是关于一个新的适应症，发现影响利伐沙班的药物选择（OR=2.422；p=0.047）。
■这项研究表明，依度沙班是最常用的抗凝剂。虽然处方心脏病专家根据背景因素选择药物，对药物治疗的依从性和来自医学代表的信息也是选择过程中的关键因素.
